Economic analysis: Erlotinib marginally cost-effective
Tuesday, February 16, 2010 - 21:28
in Health & Medicine
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective.